Estimating the probability of success (POS) of clinical trials remains a major challenge in drug development. Legacy forecasting approaches in the biopharmaceutical industry rely on historical averages stratified by development phase and therapy area, which obscures the contribution of trial design to clinical outcom...
Robert Howard, Beau Bush, Joseph Edelmann et al.· Scientific Reports· 0 citations
Blood-based biomarkers (BBMs) for Alzheimer disease (AD) have accelerated the prospect of earlier and more accessible detection of AD pathology, potentially beyond specialist settings. However, their introduction in primary care raises important questions about clinical sequencing, interpretability, pathway consequence...
Jemma Hazan, S. Salemme, Kathy Y. Liu et al.· Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.